Day: June 8, 2020

SAN JOSE, June 08, 2020 (GLOBE NEWSWIRE) — Andes Technology Corporation (TWSE: 6533), a leading supplier of high efficiency, low-power 32/64-bit RISC-V processor cores and founding member of RISC-V International, announces its Premier membership in the organization. Andes President Frankwell Lin takes his seat on the RISC-V International Board. Andes CTO and Executive VP Charlie Su becomes Vice Chair of  the RISC-V International Technical Steering Committee. The company will take an active role in the upcoming 2020 RISC-V Summit. Andes’ increased participation in RISC-V International reflects the growing demand for its broad family of RISC-V cores including its highly demanded RISC-V cores with DSP or vector extensions. As a result, Andes Technology is growing its U.S. footprint by expanding its R&D and applications engineering...

DEERFIELD, Ill., June 08, 2020 (GLOBE NEWSWIRE) — RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today announced that it has completed the filing of its 2019 Form 10-K and has completed its previously announced financial statement restatement.The Company has also completed its previously announced internal investigation of certain accounting matters, including the Company’s revenue recognition practices for certain contractual arrangements, primarily with OEM customers involving the accounting treatment, financial reporting and internal controls related to such arrangements. The Company revised its financial statements to correct for errors, and has filed restated audited consolidated financial statements for the fiscal years ended December 31, 2016, 2017 and 2018, selected financial data for the...

HAMILTON, Bermuda, June 08, 2020 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced the presentation of 28-day clinical outcomes data from the open-label treatment protocol with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation at the European E-Congress of Rheumatology (EULAR) 2020. The company also announced an active investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for its global placebo-controlled Phase 2/3...

INDIANAPOLIS, June 08, 2020 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the second fiscal quarter ended April 30, 2020. Hurco recorded a net loss of $3,927,000, or $(0.58) per diluted share, for the second quarter of fiscal 2020, compared to net income of $5,252,000, or $0.76 per diluted share, for the corresponding period in fiscal 2019. For the first six months of fiscal 2020, Hurco reported a net loss of $4,820,000, or $(0.71) per diluted share, compared to net income of $11,906,000, or $1.73 per diluted share, for the corresponding period in fiscal 2019.Sales and service fees for the second quarter of fiscal 2020 were $37,126,000, a decrease of $33,548,000, or 47%, compared to the corresponding prior year period, and included an unfavorable currency impact of $438,000, or less than 1%,...

MINNEAPOLIS, June 08, 2020 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today the appointment of Phil Ebeling as Chief Operating Officer. Mr. Ebeling is an accomplished global healthcare executive with broad experience in product innovation, strategic planning and business development. In this newly created role at Inspire, he will be responsible for the oversight and leadership of operations, quality assurance, clinical research, regulatory affairs, and business development activities.“At Inspire, we continue to accelerate our growth even during these challenging times. As such, it is imperative that we have the optimal...

RICHMOND, Calif., June 08, 2020 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,747,704 of its shares of common stock, at a purchase price of $4.5145 per share, in a registered direct offering priced at-the-market under Nasdaq Rules. The Company has also agreed to issue to the investors in a concurrent private placement warrants to purchase up to an aggregate of 873,852 shares of common stock. The closing of the offering is expected to occur on or about June 10, 2020, subject to the satisfaction of customary closing conditions.Ekso Bionics® is a leading developer...

TORONTO, June 08, 2020 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries“), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce  that its wholly-owned subsidiary Blueberries SAS entered into a collaboration agreement (the “Partnership“) with Medicanmentos de Cannabis SAS (“medcann”), to develop, and produce Tetrahydrocannabinol (“THC”) cannabis extracts for the international market.Blueberries will develop a Research and Development (“R&D”) project with medcann to produce commercial THC dominant extracts. The Company will utilize its extraction capabilities to process the THC dominant cannabis flower cultivated by medcann. In 2018, medcann became the first and only company to obtain...

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will host a conference call and webcast to review the status and timeline to results for the company’s three ongoing clinical trials including the Phase 3 trial of OTIVIDEX® in Ménière’s disease at 4:30 p.m. EDT / 1:30 p.m. PDT on June 15, 2020. This call is consistent with Otonomy’s previously announced plan to provide an update on the timing guidance, which had been pulled in April as a result of the COVID-19 pandemic. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 3655435. A live webcast of the call will be available online in the...

SANTA CLARA, Calif., June 08, 2020 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced that Teri Little has joined the company as senior vice president and chief legal officer. Previously, Ms. Little served as executive vice president, chief legal officer and corporate secretary at KLA Corporation where she led the legal affairs of the company worldwide, including corporate securities and governance, M&A, intellectual property, commercial, employment, compliance and litigation.“As our new chief legal officer, Teri brings broad legal experience as well as deep knowledge and understanding of the semiconductor industry and our customers,” said Gary Dickerson, president and CEO. “As we enter the era of artificial intelligence and big data, Applied’s opportunities have never been greater and Teri’s leadership and insight...

–  Six-month data from low-dose cohort expected in Q4 2020NEW YORK and BASEL, Switzerland, June 08, 2020 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has completed enrollment in the low-dose cohort of the Phase 1/2 (“Stage 1”) study for Type II (late infantile and juvenile onset) GM1 patients evaluating safety, tolerability, and exploratory measures of efficacy at a dose of 1.5×1013 vg/kg delivered intravenously. Currently, the study is on track to report 6-month data (n=5) from the low-dose cohort of the AXO-AAV-GM1 clinical trial by Q4 2020. Additionally, the investigational new drug (IND) filing has been amended to expand the program to include Type I (infantile) patients and to evaluate...